Evabosmig
Based on 1 Customer Validation
Evabosmig (AGA2118) is a humanized bispecific monoclonal antibody targeting sclerostin (SOST/sclerostin) and DKK1. SOST and DKK1 are two key secreted negative regulators of the intramedullary Wnt/β-catenin pathway. Evabosmig possesses activities to induce bone formation, inhibit bone resorption and increase bone mineral density. Evabosmig is applicable for research related to osteoporosis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 97.91%
- CAS. Nr.: 3061142-96-6
- Molecular Weight:145.18 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
Target
SOST/Sclerostin & DKK1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG4-kappa
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized SOST Protein, Human (HEK293, HY-P70756) can bind Evabosmig. The ED50 for this effect is 361 ng/mL. -
Loaded Evabosmig on biosensor, can bind DKK-1 Protein, Human (HEK293, HY-P7155A) with an affinity constant of 6.75E-10 M as determined in BLI assay.
Chemical Information
-
CAS. Nr. 3061142-96-6
-
Appearance Liquid
-
Molecular Weight 145.18 kDa
-
Color Colorless to light yellow
-
SMILES
[Evabosmig]
-
Synonyms
AGA2118
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Osteoclast differentiation from monocyte/macrophage precursors
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)